The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.
Similar Posts
Disposable Surgical Stapler Cartridge Correction: Ethicon Endo-Surgery, LLC Issues Correction for Endopath Echelon to Address Inadvertent Lockout During Surgical Procedures
Ethicon Endo-Surgery is correcting the Endopath Echelon due to a potential surgical lockout that stops cutting or stapling and requires extra removal steps.Nubratori, Inc. Torrance, CA. 483 issued 12/11/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 12/11/2025
Short Title (70 char) Nubratori, Inc. Torrance, CA. 483 issued 12/11/2025
FEI Number 3010166491
Firm Name Nubratori, Inc.
Record Type 483
State CA
Establishment Type Outsourcing FacilityInfluenza (Flu) Antiviral Drugs and Related Information
Flu is a serious disease, caused by influenza viruses, that can lead to hospitalization and even death. Your best defense is vaccination, which provides important protection from flu and its potential complications.Office of Prescription Drug Promotion (OPDP) News
Review the latest news from the Office of Prescription Drug Promotion.New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers
New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and AnswersFDA In Brief: FDA provides guidance on improving the agency’s interactions with product developers to make the drug development process more informed and efficient
FDA announces two new guidances to support enhanced communication with drug developers, help make the development process more informed and efficient